Evidence map›Paper›PMID 40001139›Full record

ArticleBMC medicine2025

Anti-hypertensive medication adherence, socioeconomic status, and cognitive aging in the Chinese community-dwelling middle-aged and older adults ≥ 45 years: a population-based longitudinal study.

Chenglong Li, Daijun He, Yufan Liu, Chao Yang, Luxia Zhang

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Recent topics in hypertensive dementia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chenglong LiNational Institute of Health Data Science at Peking University, Beijing, 100191, China.
Daijun HeRenal Division, Department of Medicine, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Yufan LiuCapital Medical University, Beijing, China.
Chao YangRenal Division, Department of Medicine, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Luxia ZhangNational Institute of Health Data Science at Peking University, Beijing, 100191, China. zhanglx@bjmu.edu.cn.

Funding

CAMS Innovation Fund for Medical Sciences 2019-I2M-5-046Chinese Scientific and Technical Innovation Project 2030 2018AAA0102100National Key Research and Development Program of China 2022YFF1203001National Natural Science Foundation of China 72125009Postdoctoral Fellowship Program of CPSF GZC20230170
6 · The paper itself

Abstract

backgroundIt remains unclear whether anti-hypertensive medication use is associated with cognitive aging in general Chinese middle-aged and older adults, as well as the interplay with socioeconomic status (SES). We aim to examine associations of anti-hypertensive medication adherence, SES, and cognitive aging in Chinese middle-aged and older adults.

methodsOur study was based on the China Health and Retirement Longitudinal Study, an ongoing longitudinal national survey recruiting community-dwelling adults aged ≥ 45 years. Baseline anti-hypertensive medication use was assessed at wave 1. Longitudinal adherence to anti-hypertensive medication was assessed during waves 1 and 2. SES was assessed using income, education, employment, and medical insurance. The annual rate of cognitive change was assessed using cognitive Z scores. Linear mixed models were used to examine longitudinal associations.

resultsA total of 9229 participants were included (mean [SD] age: 57.1 [8.9] years; men: 50.8%). After controlling for blood pressure and other characteristics, participants taking anti-hypertensive medication at baseline, compared to participants not using medication, had a significantly decelerated decline in global cognition (β = 0.014; 95% confidence interval [CI], 0.003 to 0.025 SD/year; P = 0.01) and memory (β = 0.021; 95% CI, 0.008 to 0.034 SD/year; P = 0.001), respectively. Similarly, participants with high anti-hypertensive medication adherence during follow-up had slower declines in global cognition (β = 0.014; 95% CI, 0.002 to 0.027 SD/year; P = 0.02) and memory (β = 0.023; 95% CI, 0.008 to 0.038 SD/year; P = 0.003), compared to the low adherence group. There were no significant differences in cognitive decline between hypertension participants using or persistently adhering to medication and normotension participants. The SES significantly interacted with anti-hypertensive medication in associations with cognitive aging, with more evident associations observed in low SES subgroup (all P for interaction < 0.05). Several sensitivity analyses were conducted, observing consistent findings.

conclusionsAdhering to anti-hypertensive medication was associated with decelerated cognitive aging in Chinese community-dwelling middle-aged and older adults, especially in participants with low SES. These findings indicate that promoting anti-hypertensive medication use could be important to achieve healthy and inclusive cognitive aging in general Chinese middle-aged and older adults living with hypertension.

Indexed as

Antihypertensive AgentsCognitive AgingHypertensionMedication AdherenceSocial ClassAgedChinaEast Asian PeopleFemaleHumansIndependent LivingLongitudinal StudiesMaleMiddle AgedAntihypertensive AgentsAnti-hypertensive medicationCognitive declineDementiaHypertension

Identifiers

PMID40001139
PMCPMC11863513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.